Modern ideas about juvenile dermatomyositis part 2: Activity assessment and treatment
|
01.09.2019 |
Podchernyaeva N.
Konevina M.
Tikhaya M.
|
Pediatriya - Zhurnal im G.N. Speranskogo |
10.24110/0031-403X-2019-98-5-135-146 |
0 |
Ссылка
© 2019, Pediatria Ltd. All rights reserved. In the article the authors present relevant information on the criteria for assessing the activity of juvenile dermatomyositis (JDM) and modern approaches to its treatment. In clinical practice, various scales are currently used to assess the overall JDM activity and severity of damage to various organs, primarily muscles and skin. The article provides modern recommendations for JDM treatment: The use of glucocorticosteroids, disease-modifying antirheumatic drugs (methotrexate, calcineurin inhibitors, cyclophosphamide, mycophenolate mofetil, azathioprine, hydroxychloroquine, intravenous immunoglobulin), genetically engineered drugs (rituximab, infliximab, adalimumab, golimumab, certolizumab, etanercept), as well as promising new drugs and methods of maintenance therapy. The modern JDM treatment algorithm is described.
Читать
тезис
|